Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-09-04
2007-09-04
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S001530, C530S326000, C530S327000, C530S328000
Reexamination Certificate
active
10716846
ABSTRACT:
Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.
REFERENCES:
patent: 4912120 (1990-03-01), Castelhano et al.
patent: 4929630 (1990-05-01), Castelhano et al.
patent: 5834428 (1998-11-01), Drucker
patent: 6197356 (2001-03-01), Girsh
patent: 6319726 (2001-11-01), Schuppan et al.
patent: 6410550 (2002-06-01), Coe et al.
patent: 2001/0036639 (2001-11-01), Fine
patent: 2002/0076834 (2002-06-01), Detlef et al.
patent: 2004/0241664 (2004-12-01), Dekker et al.
patent: 0 905 518 (1999-03-01), None
patent: WO94/26774 (1994-11-01), None
patent: WO 01/25793 (2001-04-01), None
patent: WO 03/068170 (2003-08-01), None
Piper et al. High selectivity of human tissue transglutaminase for immunoactive gliadin peptides: implications for celiac sprue.Bichemistry. Jan. 8, 2002;41(1):386-93.
Ahnen et al., Intestinal Aminooligopeptidase in vivo Synthesis on Intracellualar Membranes of Rat Jejunum, J. Biol. Chem., (1982), 257: 12129-35.
Arentz-Hansen et al., The Intestinal T Cell Response to α-Gliadin in Adult Celiac Disease is Focused on a Single Deamidated Glutamine Targeted by Tissue Transglutaminase, J. Exp. Med., (2000), 191: 603-12.
Bordusa et al., The Specificity of Prolyl Endopeptidase FromFlavobacterium meningoseptum: Mapping the S′ Subsites by Positional Scanning via Acyl Transfer, Bioorg. Med. Chem., (1998), 6: 1775-80.
Lahteenoja et al., Local Challenge on Oral Mucosa With an α-Gliadin Related Synthetic Peptide in Patients With Celiac Disease, Am. J. Gastroenterol., (2000), 95: 2880.
Schuppan, Detlef, Special Reports and Reviews Current Concepts of Celiac Disease Pathogenesis. Gastroenterology, (2000), 119: 234-42.
Wieser, Herbert, The Precipitating Factor in Coeliac Disease, Baillieres Clin Gastroenterol, (1995) . 9(2):191-207.
Yoshimoto et al., Prolyl Endopeptidase FromFlavobacterium meningosepticum: Cloning and Sequencing of the Enzyme Gene, J. Biochem., (1991), 110: 873-8.
Greenberg, C., et al., “Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues,” (1991)FASEB J., 5:3071-3077.
Hitomi, K., et al., “GTP, an inhibitor of transglutaminases, is hydrolyzed by tissue-type transglutaminase (TGase 2) but not by epidermal-type transglutaminase (TGase 3),” (2000)Biosci. Biotechnol. Biochem., 64(3):657-659.
Sardy, M., et al., “Epidermal transglutaminase (TGase 3) is the autoantigen ofDermatitis herpetiformis,” (2002)J. Exp. Med., 195(6):747-757.
Choi Kihang
Khosla Chaitan
Audet Maury
Bozicevic Field & Francis LLP
Sherwood Pamela J.
The Board of Trustees of the Leland Stanford Junior University
Tsang Cecilia J.
LandOfFree
Drug therapy for Celiac Sprue does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drug therapy for Celiac Sprue, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug therapy for Celiac Sprue will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3801195